金币
UID10147
帖子
主题
积分15267
注册时间2011-12-15
最后登录1970-1-1
听众
性别保密
|
欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
本帖最后由 圣剑之心 于 2013-6-28 14:57 编辑
2013年6月25-27日,由欧洲博闻展览咨询有限公司(UBM Live)和中国医药保健品进出口商会主办,上海博华国际展览有限公司(UBM Sinoexpo)协办的“第十三届世界制药原料中国展”暨“2013世界合同定制服务中国展”(CPhI, ICSE & BioPh China 2013)以及“2013世界制药机械、包装设备与材料中国展”暨“2013世界生化、分析仪器及实验室装备中国展”(P-MEC, InnoPack & LABWorld China 2013)在上海新国际博览中心成功举行,圆满落幕。本届CPhI中国展观众人次再创新高,高达44984人次,比去年增长10%。蒲公英制药技术论坛作为此次会展的官方合作媒体全程参与了这次展会的报道。同时蒲公英制药技术论坛(http://ouryao.com)和中天昊宇公司合作设置了展台。2013年6月26日蒲公英制药技术论坛与Sparta Systems合作,共同为蒲友带来一场精彩的研讨会。
近年来,我国原料药产业发展迅速,已成为世界最大的原料药生产国和出口国,目前外贸形势仍处于持续性增长阶段,行业前景乐观。新医药体制改革的不断深入和相关配套措施的不断出台促进了我国医药制造业的产业结构变迁,为中国制药产业带来了巨大的机遇。行业的蓬勃发展为"世界制药原料中国展"(CPhI, ICSE & BioPh China)提供了良好的发展契机。
历经13年的沉绽与升华"世界制药原料中国展"的品牌效应深入人心。与此同时,展会的举办地--上海,在经济发展、科技创新、城市建设等方面取得了飞跃的发展,为国内外参观者提供了高效、便捷、贴心的服务。巨大的市场潜力、日益完善的医改政策、优越的地理位置、四通八达的城市交通、先进的基础设施环境、世界各国的关注--这些条件使得本次展会的举办形成了"天时,地利,人和"的绝佳环境。
展会将汇集医药市场最前沿的信息,为来自20多个国家的2500余家展商、4万余名专业采购商呈现一个全方位的一站式的制药工业贸易平台。
据记者了解,会议采用了"展-会"联动的形式,让业界及时把握中国乃至全球医药市场的最新动态,为企业进一步开拓市场创造机遇。
为更好地促进观众与企业之间的信息互动,满足观众与企业了解行业前沿信息和技术交流的需求,展会期间,主办方将结合国内外最新政策法规、行业热点话题和实用技术应用,精心策划高端论坛、专业研讨会、展商技术交流会及采购配对活动互动平台等。
另外,为了保护产品的知识产权,主办方在展会前将对所有参展公司的产品目录进行筛查,严禁侵权产品的企业参展,以维护"中国制造"在国际舞台上的形象。展会期间,主办方与上海市知识产权局在现场联合成立展会知识产权办公室,接受知识产权权利人的投诉并处理相关事宜。同时,主办方也将联手药品监督管理部门,现场对展品进行质量监督抽查。
目前,中国医保商会已制定了抵制非法药品工作方案,拟利用展会这一平台,配合国家药品监管部门坚决抵制和打击有关违法行为,以维护行业形象和正常经营秩序。
目前,Merck、Roquette、Johnson Matthey、Rohm & Haas、Evonik Degussa、Novasep、华药、石药、哈药、东药、上药、海正、华海、鲁抗等国内外领军企业均成为了世界制药原料中国展的固定参展客商。国内中小医药企业也踊跃报名参展,并纷纷扩大展示面积,加强品牌宣传。
作为亚洲地区最大规模和最高层次的制药工业界国际展览平台,展会在加快推动国内医药企业走向国际市场的同时,也促进了世界医药贸易的繁荣与整个医药行业的快速发展。
In recent years, China's BPC industry has developed rapidly and China has become the world's largest BPC producer and exporter. Currently, the foreign trade is still at the stage of constant growth with promising prospect. The constant progress of new medical system reform and supporting measures has promoted the industrial structure change of China's pharmaceutical manufacturing industry, which brings great opportunities for China's pharmaceutical industry. The prosperous industrial development provides favorable development opportunity for "CPhI, ICSE & BioPh China".
The exhibition will gather the most cutting-edge information of the pharmaceutical markets and present a comprehensive one-stop pharmaceutical industry trade platform for over 2,500 exhibitors and over 40,000 professional purchasers coming from more than 20 countries.
According to the reporter, the meeting adopts the form of "display-meeting" to make the world timely grasp the latest news of Chinese and global pharmaceutical markets and create opportunities for further developing markets. In order to better promote the information interaction between the audience and enterprises, and satisfy the demand of the audience and enterprises for the latest industrial information and technological exchanges, the organizer during the exhibition will meticulously plan high-end forum, professional seminar, technological exchange symposium among exhibitors and purchase matching and other activities in terms of domestic and international latest policies, regulations, hot topics of the industry and practical technology application.
In order to protect IPR, the organizer will screen the product catalogue of all participating companies before the exhibition, forbid enterprises with infringing products to participate and protect the image of "Made in China" on the international stage. During the exhibition, it will establish exhibition intellectual property office on the site together with Shanghai Intellectual Property Administration to receive the complaints from the owners of intellectual property and deal with relevant matters. Meanwhile, the organizer will work with the drug supervision and administration department to conduct random check on the quality of on-spot exhibits.
At present, China Chamber of Commerce has formulated work solutions for resisting illegal drugs. It plans to use the exhibition platform to resist and crack down on illegal behaviors in partnership with the national drug supervision and administration department so as to maintain the industrial image and normal operation order.
蒲公英制药技术论坛发布!
如果这篇文章侵犯了您的权利,请联系我们。 |
|